Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database

Breast Cancer Research and Treatment

Volumn 76, Issue 1, 2002, Pages 27-36

  Anderson, William F ^a   Chatterjee, Nilanjan ^a   Ershler, William B ^b   Brawley, Otis W ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Institute for Advanced Studies in Aging and Geriatric Medicine   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Age specific rates (or risks); Breast cancer model; Estrogen receptor ; Prognostic factors

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER EPIDEMIOLOGY; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; DATA BASE; HEALTH SURVEY; HISTOGRAM; HISTOLOGY; HUMAN; MENOPAUSE; NEGRO; NONHUMAN; PHENOTYPE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RAT; STANDARD;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; MIDDLE AGED; PHENOTYPE; RECEPTORS, ESTROGEN; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 0036838070     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020299707510     Document Type: Article

References (57)

1. Henderson IC, Patek AJ: The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 52: 261-288, 1998
2. Easton D: Breast cancer - not just whether but when? [In Process Citation]. Nat Genet 26: 390-391, 2000
3. Hellman S: Natural history of small breast cancers. J Clin Oncol 12: 2229-2234, 1994
4. Moolgavkar SH, Day NE, Stevens RG: Two-stage model for carcinogenesis: epidemiology of breast cancer in females. J Natl Cancer Inst 65: 559-569, 1980
5. Tarone RE, Chu KC: The greater impact of menopause on El-phon Elt breast cancer incidence: a possible explanation (United States) Cancer Causes Control, 3: 7-14, 2002
6. Auer GU, Fallenius AG, Erhardt KY, Sundelin BS: Progression of mammary adenocarcinomas as reflected by nuclear DNA content. Cytometry 5: 420-425, 1984
7. Pallis L, Skoog L, Falkmer U, Wilking N, Rutquist LE, Auer G, Cedermark B: The DNA profile of breast cancer in situ. Eur J Surg Oncol 18: 108-111, 1992
8. Iglehart JD, Kerns BJ, Huper G, Marks JR: Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Treat 34: 253-263, 1995
9. Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R: Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 69: 1174-1181, 1992
10. Robertson JF: Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 73: 5-12, 1996
11. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000
12. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S. Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001
13. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA: Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the Surveillance, Epidemiology, and End Results database. J Clin Oncol 19: 18-27, 2001
14. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW: Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92: 37-45, 2001
15. Simpson JF, Page DL: Status of breast cancer prognostication based on histopathologic data. Am J Clin Pathol 102: S3-S8, 1994
16. Percy C, Holten VV, Muir C (eds): International Classification of Diseases for Oncology. World Health Organization, Geneva, 1990
17. Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic Research: Principles and Quantitative Methods. John Wiley & Sons, New York, 1982
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
19. Peto R, Peto J: Asymptomatically efficient rank invariant test procedures. J R Stat Soc A 135: 185-198, 1972
20. Cox DR: Regression models and life-tables. J R Stat Soc B 34: 187-220, 1972
21. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2: 1102-1109, 1984
22. Clemmesen J: Carcinoma of the breast. Br J Radiol 21: 583-590, 1948
23. Anderson E: Possible relationship between menopause and age at onset of breast cancer. Cancer 3: 141-410, 1950
24. Brinton LA, Benichou J, Gammon MD, Brogan DR, Coates R, Schoenberg JB: Ethnicity and variation in breast cancer incidence. Int J Cancer 73: 349-355, 1997
25. Velentgas P, Daling JR: Risk factors for breast cancer in younger women. J. Natl Cancer Inst Monogr 16: 15-24, 1994
26. Edwards MJ, Gamel JW, Vaughan WP, Wrightson WF: Infiltrating ductal carcinoma of the breast: the survival impact of race. J Clin Oncol 16: 2693-2699, 1998
27. Yasui Y, Potter JD: The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 10: 431-437, 1999
28. Armitage P, Doll R: A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer 11: 161-169, 1957
29. Armitage P, Doll R: The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 8: 1-12, 1954
30. Lilienfeld AM, Johnson EA: The age distribution in female breast and genital cancers. Cancer 8: 875-882, 1955
31. Peto J, Mack TM: High constant incidence in twins and other relatives of women with breast cancer [In Process Citation]. Nat Genet 26: 411-414, 2000
32. Bertram JS: The molecular biology of cancer. Mol Aspects Med 21: 167-223, 2000
33. Loeb LA: A mutator phenotype in cancer. Cancer Res 61: 3230-3239, 2001
34. Nandi S, Guzman RC, Yang J: Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92: 3650-3657, 1995
35. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC: A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 60: 4026-4029, 2000
36. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998
37. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286: 2251-2556, 2001
38. Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356: 1876-1881, 2000
39. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H: Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes [see comments]. Cancer 83: 310-319, 1998
40. Phillips KA: Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18: 107S-112S, 2000
41. Jordan VC, Allen KE: Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16: 239-251, 1980
42. Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12: 419-424, 1976
43. Early breast cancer trialist's collaborative group. Systemic Treatment of Early Breast Cancer by Hormonal, Cytotoxic, or Immune Therapy. 133 Randomized Trials Involving 31,000 Recurrences and 24,000 Death Among 75,000 Women, pp. 1-15, 71-85, 1992
44. Buchanan RB, Blamey RW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG: A randomized comparison of tamoxifen with surgical oo-phorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4: 1326-1330, 1986
45. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL: Breast cancer risk after bilateral prophylactic oo-phorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475-1479, 1999
46. Peto J, Houlston RS: Genetics and the common cancers. Eur J Cancer 37 (Suppl 8): 88-96, 2001
47. Frey CM, McMillen MM, Cowan CD, Horm JW, Kessler LG: Representativeness of the surveillance, epidemiology, and end results program data: recent trends in cancer mortality rates. J Natl Cancer Inst 84: 872-877, 1992
48. De Waard F: Premenopausal and postmenopausal breast cancer: one disease or two? J Natl Cancer Inst 63: 549-552, 1979
49. De Waard F, Baanders-van Halewijn EA, Huizinga J: The bimodal age distribution of patients with mammary carcinoma. Cancer 17: 141-151, 1963
50. De Waard F, De Laive JWJ, Baanders-van Halewijn EA: On bimodal age distribution of mammary carcinoma. Br J Cancer 14: 437-448, 1960
51. von Pirquet C. Allergie des Lebensalters, die bosartigen Geschwulste (Allergy of age, the Malignant Tumors), Thieme Verlag, Leipzig, Germany, 1930
52. Muguti GI: Experience with breast cancer in Zimbabwe. J R Coll Surg Edinburgh 38: 75-78, 1993
53. Chie WC, Chen CF, Lee WC, Chen CJ, Lin RS: Age-period-cohort analysis of breast cancer mortality. Anticancer Res 15: 511-515, 1995
54. Sant M, Gatta G, Micheli A, Verdecchia A, Capocaccia R, Crosignani P, Berrino F: Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer 27: 981-984, 1991
55. Clemmesen J, Busk T: Cancer mortality among men and women in Denmark, England, and Switzerland. V. Incidence of accessible and inaccessible cancers in Danish towns and rural areas. Cancer Res 9: 415-421, 1949
56. Moolgavkar SH, Lee JA, Hade RD: Comparison of age-specific mortality from breast cancer in males in the United States and Japan. J Natl Cancer Inst 60: 1223-1225, 1978
57. Thomas DB: Breast cancer in men. Epidemiol Rev 15: 220-231, 1993